Tag - BMKDF

Developments

BioMark Diagnostics receives CIPO and EPO patent allowances for early-stage lung cancer blood test

BioMark Diagnostics (CSE: BUX; FSE: 20B; OTCQB: BMKDF) has announced the receipt of patent allowances from both the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) for its...

June 23, 2026

Developments

Frontiers in Oncology to publish BioMark’s research on ML model for lung cancer detection

BioMark Diagnostics (CSE: BUX; FSE: 20B; OTCQB: BMKDF) has announced that the peer-reviewed journal Frontiers in Oncology has accepted for publication the company’s research on a machine learning (ML) predictive model...

January 15, 2026

Tag - BMKDF

BioMark Diagnostics receives CIPO and EPO patent allowances for early-stage lung cancer blood test

Frontiers in Oncology to publish BioMark’s research on ML model for lung cancer detection

Subscribe